TL;DR
- What it is: CJC-1295 is a growth hormone releasing hormone (GHRH) analog; Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist. Run together they produce pulsatile GH release that mimics the body’s native pattern.
- Mechanism: Two independent inputs to the pituitary somatotroph — the GHRH arm (CJC) tells the cell to release GH, the ghrelin arm (Ipamorelin) amplifies the pulse. Hit both, get a bigger, cleaner pulse than either alone.
- Who it’s for: Men 35+ wanting restorative GH elevation without the fat face, water retention, and IGF-1 ceiling of exogenous HGH — plus anyone wanting better sleep, recovery, and skin quality.
- Differentiator: Unlike MK-677, this stack preserves natural GH pulsatility, doesn’t elevate cortisol or prolactin, and doesn’t cause the relentless hunger and water retention of oral secretagogues.
- Natural Plus angle: Pulsed subcutaneous dosing pre-bed to align with natural nocturnal GH release — not the 24/7 elevation that desensitizes receptors.
Deep Biochemistry: Two Independent Levers on the Same Cell
The pituitary somatotroph — the cell that stores and releases growth hormone — has two gates. One gate is opened by GHRH (growth hormone releasing hormone), the endogenous hypothalamic peptide that signals “release stored GH.” The second gate is opened by ghrelin binding to GHSR-1a, the ghrelin receptor. Ghrelin was originally identified as a hunger hormone, but its older evolutionary job is amplifying GH pulses.
CJC-1295 is a synthetic GHRH analog. The modified version most people refer to as “CJC-1295” in peptide forums is actually cjc-1295 without dac (no drug affinity complex) — also known as Mod GRF 1-29. The DAC version has a 6-8 day half-life; the no-DAC version is about 30 minutes. The no-DAC version is the right choice for pulse-mimicking protocols because it lets GH spike and fall naturally, rather than creating sustained GH elevation that downregulates receptors and stops feeling like anything by week 4.
Ipamorelin is a pentapeptide with high GHSR-1a selectivity. This matters because earlier GH secretagogues (GHRP-6, GHRP-2, Hexarelin) also activated the cortisol and prolactin release axes. Ipamorelin is clean — essentially no cortisol or prolactin elevation at standard doses. Half-life is roughly 2 hours. Binding affinity at GHSR-1a is in the low nanomolar range.
When CJC-1295 (no DAC) and Ipamorelin are co-administered subcutaneously, the two signals converge on the somatotroph within the same 30-minute window. GHRH opens the primary gate. Ipamorelin amplifies the pulse by activating the second, independent pathway. Published data shows a combined pulse approximately 2–3x larger than either compound alone — this is the rationale behind the stack.
Downstream, that GH pulse drives hepatic IGF-1 synthesis over the following 12–24 hours. IGF-1 is what actually does most of the work you associate with GH: tissue repair, lean mass preservation, connective tissue remodeling, skin collagen synthesis, and sleep architecture improvements. Elevated GH pulses at night also deepen slow-wave sleep, which is where most of the real recovery happens.
Tony Huge Laws of Biochemistry Physics: Law 5 in Action
CJC-1295 + Ipamorelin is a textbook illustration of the tony huge Laws of Biochemistry Physics — specifically Law 5, Independent Receptor Stacking. Two compounds. Two separate receptors (GHRH receptor and GHSR-1a). Both converging on the same functional outcome: GH pulse amplification. Because the receptors are independent, the signals are additive — arguably synergistic at the somatotroph level — rather than diminishing.
Compare this with the wrong stack: CJC-1295 + Sermorelin. Both are GHRH agonists. Same receptor. Stacking them is Law 5 telling you “these are in series, not parallel — you gain nothing.” That’s why you never see that stack recommended by anyone who actually understands the pharmacology. But CJC + Ipa, or CJC + MK-677, or CJC + Ipa + Tesamorelin at carefully staggered times — those hit independent pathways.
The Natural Plus Protocol
The standard protocol that my underground network has converged on over years of experimentation, and what I personally run on my own cycles:
- Doses: CJC-1295 (no DAC) 100 mcg + Ipamorelin 200–300 mcg, subcutaneous, reconstituted in bacteriostatic water.
- Frequency: 1–3 injections per day. The minimum effective protocol is a single pre-bed shot (45 minutes before sleep), which aligns with the natural GH peak during slow-wave sleep. The “bodybuilder” protocol is three daily shots (morning fasted, pre-workout, pre-bed).
- Timing rules: Do not eat 30 minutes before or after injection. Insulin and glucose blunt the GH pulse. Fatty meals are especially suppressive.
- Cycle length: 8–12 weeks on, 4 weeks off. Pulsatile dosing resists receptor downregulation far better than continuous-agonist protocols like MK-677, so cycles can run longer before requiring a break.
- Reconstitution: 2 ml bacteriostatic water per 5 mg vial of CJC-1295 or Ipamorelin. Store reconstituted vials at 2–8°C. Stable for 30 days reconstituted.
- Injection site: Rotate subcutaneous sites — abdominal fat, thigh, glute. Insulin syringe, 29-31 gauge, 0.5 inch needle.
- Bloodwork: IGF-1 baseline, week 4, week 8. A well-running protocol takes IGF-1 from a typical middle-aged baseline of 150 ng/mL into the 250–320 range, which is the upper quintile of young-adult reference. If it’s not moving, the peptides are underdosed, bunk, or the user is eating too close to injection time.
What I see people get wrong: they inject right after dinner, wonder why they feel nothing, and quit. Eat your last meal two hours before bed, inject 45 minutes before sleep on an empty stomach, and wake up the next morning having slept like you were 25 again.
Stacking Recommendations
Per Law 5 of the Tony Huge Laws of Biochemistry Physics, these are the independent-pathway stacks that actually synergize:
| Stack Compound | Pathway | Why It Synergizes | Product Link |
|---|---|---|---|
| BPC-157 | VEGF / tissue repair | Elevated IGF-1 primes tissue for repair; BPC-157 accelerates it. No receptor overlap. | SwissChems |
| Tesamorelin | GHRH (longer-acting) | Different agonist kinetics at same receptor — debatable stack. Better used on off-cycle months from CJC. | SwissChems |
| MK-677 (alternative, not concurrent) | GHSR-1a (oral) | Same receptor as Ipamorelin — don’t stack together. Rotate on off-cycles for continuous GH support. | SwissChems |
| GHK-Cu | Copper peptide / collagen | Elevated IGF-1 plus GHK-Cu drives skin and hair quality faster than either alone. | SwissChems |
| Low-dose testosterone or LGD-4033 | Androgen receptor | AR activation + IGF-1 elevation is the classic recomp stack. Independent pathways. | Enhanced Labs |
Target Audience
The sweet spot for CJC-1295 + Ipamorelin is men 35 and older who have declining natural GH output (somatopause is real and starts around age 30, dropping 14% per decade), who want improved recovery and sleep, and who don’t want the commitment or cost of exogenous HGH. Specifically:
- Lifters noticing slower recovery from workouts that used to be easy.
- Men with deteriorating sleep quality — fewer slow-wave cycles, lighter sleep, waking unrefreshed.
- Athletes rehabbing injuries where elevated IGF-1 accelerates tendon and ligament remodeling.
- Anyone on TRT who wants to round out their protocol with GH axis support without going to full pharmaceutical HGH.
- Men concerned with visible aging — skin thickness, collagen density, hair quality.
It’s the wrong compound for: anyone under 25 whose natural GH output is already at lifetime peak, anyone with active cancer (IGF-1 elevation is contraindicated), and anyone unwilling to inject subcutaneously every day.
Timeline / What to Expect
| Timeframe | What to Expect |
|---|---|
| Week 1–2 | Deeper sleep the first night. Vivid dreams return (a reliable sign the GH pulse is hitting). Slight water retention at injection sites. IGF-1 not yet moved on labs. |
| Week 4 | IGF-1 climbing (expect +50–100 ng/mL over baseline). Faster recovery between heavy workouts. Improved skin texture. Minor joint creakiness diminishing. |
| Week 8 | IGF-1 in the 250–300 ng/mL range if protocol is dialed. Visible body composition improvement (2–4 lb lean mass, slight bodyfat reduction), thicker skin, better nails. Sleep quality noticeably above baseline. |
| Week 12 / Post-cycle | IGF-1 should hold in the upper-normal range for 2–4 weeks post-cycle, then drift back toward baseline. The recomposition effect persists if training and nutrition stay dialed. Plan the next cycle after a 4-week washout. |
Interesting Perspectives
Why DAC CJC-1295 is the wrong choice for most users. The DAC (drug affinity complex) version was engineered for sustained-release once-weekly dosing — a convenience feature, not a pharmacological improvement. But sustained GHRH signaling saturates the somatotroph’s releasable GH pool and downregulates the receptor. After about 4 weeks of DAC, your pulses flatten out and you feel nothing. The no-DAC version’s short half-life is actually the feature, not a bug — it preserves pulsatility, which is what the somatotroph evolved for. This is a Law 4 (Self-Regulating Systems) application: pulse to work with homeostasis, saturate to fight it.
Cross-domain finding: GH pulses and memory consolidation. Slow-wave sleep is when declarative memory consolidates. GH peaks during SWS — and causes SWS. Boost the pulse, deepen the sleep, improve next-day cognitive performance. I’ve noticed this repeatedly on my own protocol and in the underground network: pre-bed CJC+Ipa users consistently report sharper recall and better mental clarity in the morning, even beyond the fatigue-recovery story.
The “GH face” myth. Exogenous HGH at 4+ IU/day causes jaw broadening and intestinal fascia thickening over years — the classic “GH gut” seen in pro bodybuilders. CJC+Ipa at physiological pulse doses has never been observed to produce this. The reason is the IGF-1 ceiling: peptide stacks top out around 300 ng/mL IGF-1, which is upper-normal young adult. Exogenous HGH pushes 500+ ng/mL, which is supraphysiological. The peptide stack stays within the body’s own evolutionary range.
Contrarian take on “just use HGH.” Forum bros will tell you CJC+Ipa is a waste and you should just run real HGH. For most users in the 35–60 age bracket chasing restoration and recovery rather than pharmacological lean mass, that advice is wrong. HGH costs 5–10x more, requires daily injections anyway, causes bloating and water retention, and produces insulin resistance over time. CJC+Ipa produces 60–70% of the benefit at 10–15% of the cost, without the metabolic downside. The only population for whom HGH is genuinely better is competitive bodybuilders seeking pharmacological IGF-1 elevation — a small, specific group.
Morning injection vs pre-bed. Pattern noticed across the network: people prioritizing fat loss benefit from morning fasted injection (maximizes lipolytic GH action on empty stomach), while people prioritizing recovery and sleep benefit from pre-bed injection. Three-per-day protocols hit both — but are probably overkill for anyone who isn’t competing. Single pre-bed dosing is where most of the value sits for 80% of users.
References
- Sigalos JT, Pastuszak AW. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sex Med Rev, 2018;6(1):45-53. DOI:10.1016/j.sxmr.2017.02.004
- Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol, 1998;139(5):552-561.
- Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab, 2006;91(3):799-805.
- Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” J Clin Endocrinol Metab, 2006;91(12):4792-4797.
- Rudman D, Feller AG, Nagraj HS, et al. “Effects of human growth hormone in men over 60 years old.” N Engl J Med, 1990;323(1):1-6.
- Sattler FR. “Growth hormone in the aging male.” Best Pract Res Clin Endocrinol Metab, 2013;27(4):541-555.
- Chapman IM, Bach MA, Van Cauter E, et al. “Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects.” J Clin Endocrinol Metab, 1996;81(12):4249-4257.
FAQ
What is CJC-1295 + Ipamorelin? A peptide stack combining a GHRH analog (CJC-1295) and a selective ghrelin receptor agonist (Ipamorelin) that triggers a pulsatile, mimicked-natural release of growth hormone from the pituitary.
What’s the optimal dose? 100 mcg CJC-1295 (no DAC) plus 200–300 mcg Ipamorelin per injection, once daily pre-bed for recovery/sleep benefit, or up to three times daily for pharmacological protocols. Inject subcutaneously in a fasted window.
What are the side effects? Mild injection-site redness, occasional early-cycle water retention at injection sites, vivid dreams, brief flush or lightheadedness right after injection (subsides in minutes). No cortisol or prolactin elevation at standard doses.
What does CJC-1295 + Ipamorelin stack well with? BPC-157 (tissue repair), GHK-Cu (collagen), low-dose TRT or LGD-4033 (androgen receptor activation). Do not stack with sermorelin or tesamorelin concurrently — same receptor, diminishing returns.
Who should use this stack? Men 35+ experiencing declining GH output, slower recovery, deteriorating sleep, or visible aging. Anyone wanting GH axis support without committing to exogenous HGH.